What is CALC's current stock price?

CALC (CalciMedica, Inc.) is currently trading at $0.63 with a market cap of $9.9M.

What sector is CalciMedica, Inc. in?

CalciMedica, Inc. (CALC) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CALC a good stock to buy?

Analysts have a Buy consensus on CALC with a price target of $266.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CALC CalciMedica, Inc.

Healthcare

$0.63-0.17%ClosedMarket Cap: $9.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-8.55

P/S

0.00

EV/EBITDA

-0.06

DCF Value

$0.00

FCF Yield

-213.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

4093.0%

ROA

-227.0%

ROIC

-674.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$5.0M	$—
Q4 null	$0.00	$-10.8M	$—
FY null	$0.00	$-29.6M	$—
Q3 null	$0.00	$-7.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$266.00

Target (Median)

$392.00

Target Range

$14.00 - $392.00

0 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell

OppenheimerOutperform

2026-03-05

HC Wainwright & Co.Neutral

2026-01-29

Trading Activity

Insider Trades

View All

Stauderman Kenneth A.officer: Chief Scientific Officer

SellTue Apr 07

Roberts Eric Wdirector, 10 percent owner, officer: CHIEF BUSINESS OFFICER

SellTue Apr 07

Leheny A. Racheldirector, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER

SellTue Apr 07

Hebbar Sudarshanofficer: Chief Medical Officer

SellTue Apr 07

Dunn Michael J.officer: President and COO

SellTue Apr 07

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.82

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

Peers